GO:0046539 histamine N-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046539 histamine N-methyltransferase activity describes the catalysis of S-adenosyl-L-methionine(1+) plus histamine to N(tau)-methylhistamine, S-adenosyl-L-homocysteine and H+, the principal enzymatic route for terminating histamine signalling in mammals.
• The enzyme is encoded by HNMT, a cytosolic, S-adenosylmethionine-dependent methyltransferase that is widely expressed but is particularly important in the brain and in peripheral tissues such as the gut and heart.
• HNMT activity is a major determinant of histamine clearance: reduced or inhibited activity prolongs histamine signalling, whereas increased activity accelerates histamine inactivation.
• Altered HNMT activity has been linked to histamine intolerance, inflammatory bowel disease, idiopathic hypersomnia, narcolepsy, cardiac hypertrophy and heart failure, and to anti-HER2 treatment adaptability in breast cancer.
• Pharmacological inhibition of HNMT is being explored as a therapeutic strategy to extend wakefulness and suppress cataplexy, illustrating that this enzymatic activity is a tractable drug target.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with CRISPR library screening and bioinformatics, provide the most direct way to test causal roles of HNMT and related histamine-metabolising genes.
Description
GO:0046539 histamine N-methyltransferase activity is a molecular function term in the Gene Ontology that describes the catalysis of the reaction S-adenosyl-L-methionine(1+) + histamine = N(tau)-methylhistamine + S-adenosyl-L-homocysteine + H+. This activity is the major route for the inactivation of histamine in mammals, and it is therefore central to the control of histamine signalling in the brain and in peripheral tissues. The enzyme responsible, histamine N-methyltransferase (HNMT), is a cytosolic S-adenosylmethionine-dependent methyltransferase that transfers a methyl group to the imidazole ring of histamine, producing N(tau)-methylhistamine, which is then further metabolised and excreted. Because histamine regulates wakefulness, immune responses, gastric acid secretion and vascular tone, the activity encoded by GO:0046539 is a key node in neurobiology, immunology and cardiovascular physiology. Researchers study this activity to understand how histamine is cleared, how its dysregulation contributes to disease, and how pharmacological or genetic manipulation of HNMT can alter histamine-dependent phenotypes. The term is also relevant to precision nutrition and to biomarker discovery, since histamine metabolism varies between individuals and can influence responses to diet and therapy. This article summarises the definition, mechanism, key genes, disease links and experimental methods associated with GO:0046539, with all factual claims supported by published literature.
histamine N-methyltransferase activity At A Glance
| GO ID | GO:0046539 |
|---|---|
| GO term | histamine N-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | histamine 1-methyltransferase activity; histamine-methylating enzyme; histamine methyltransferase activity; imidazolemethyltransferase activity; S-adenosyl-L-methionine:histamine N-tele-methyltransferase activity; S-adenosylmethionine-histamine N-methyltransferase activity |
| Major function | Catalysis of S-adenosyl-L-methionine(1+) + histamine = N(tau)-methylhistamine + S-adenosyl-L-homocysteine + H+ |
| Representative gene | HNMT (histamine N-methyltransferase) |
| Substrate | Histamine |
| Cofactor / methyl donor | S-adenosyl-L-methionine (SAM) |
| Primary product | N(tau)-methylhistamine |
| Subcellular localisation | Cytosol |
| Related disease areas | Histamine intolerance, inflammatory bowel disease, idiopathic hypersomnia, narcolepsy, cardiac hypertrophy and heart failure, breast cancer treatment response |
What Is GO:0046539?
In practical terms, GO:0046539 histamine N-methyltransferase activity is the enzymatic function that methylates histamine using S-adenosyl-L-methionine as the methyl donor, yielding N(tau)-methylhistamine, S-adenosyl-L-homocysteine and a proton. It is a molecular_function term, meaning it describes what a gene product does at the biochemical level rather than where it acts or which pathway it belongs to. The activity is synonymous with histamine 1-methyltransferase activity, histamine-methylating enzyme, histamine methyltransferase activity, imidazolemethyltransferase activity, S-adenosyl-L-methionine:histamine N-tele-methyltransferase activity and S-adenosylmethionine-histamine N-methyltransferase activity. In mammals, this activity is predominantly carried out by the product of the HNMT gene, a cytosolic enzyme that terminates histamine signalling by converting histamine to a methylated metabolite.
Why Is histamine N-methyltransferase activity Important in Cell Biology?
GO:0046539 histamine N-methyltransferase activity is important because it is the principal enzymatic mechanism for terminating histamine signalling in mammals, and its dysregulation has been associated with a wide range of human conditions, including histamine intolerance, inflammatory bowel disease, sleep disorders, cardiac disease and cancer treatment response. Because histamine is a pleiotropic mediator of wakefulness, immune function, gastric secretion and vascular tone, the activity that clears it is a central control point in physiology and a promising target for pharmacological intervention.
• Terminates histamine signalling by converting histamine to N(tau)-methylhistamine, the major histamine metabolite in mammals.
• Determines histamine clearance in the brain, where astrocytic HNMT contributes to the regulation of wakefulness and brain function.
• Is linked to histamine intolerance, a condition in which reduced histamine degradation leads to adverse reactions to histamine-rich foods.
• Is implicated in inflammatory bowel disease, where altered histamine metabolism may influence intestinal inflammation and precision nutrition strategies.
• Is a therapeutic target in idiopathic hypersomnia, where HNMT inhibition has been proposed to enhance histaminergic signalling.
• Is a target in narcolepsy, where pharmacological inhibition of HNMT extends wakefulness and suppresses cataplexy in mouse models.
• Is associated with cardiac hypertrophy and heart failure, where HNMT upregulation has been reported.
• Is a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients.
• Provides a tractable enzymatic activity for CRISPR-based knockout, point-mutation, knock-in and overexpression studies.
• Supports drug discovery efforts aimed at modulating histamine clearance in neurological and peripheral disorders.
What Happens During histamine N-methyltransferase activity?
Substrate binding and methyl transfer
In simple terms: The enzyme grabs histamine and a methyl donor, then moves a methyl group onto histamine.
Histamine N-methyltransferase binds histamine and the methyl donor S-adenosyl-L-methionine (SAM) in its active site. The enzyme transfers a methyl group from SAM to the imidazole ring of histamine, forming N(tau)-methylhistamine and S-adenosyl-L-homocysteine (SAH), with release of a proton. This reaction is the principal route for histamine inactivation in mammals and is catalysed by the product of the HNMT gene.
Product formation and histamine clearance
In simple terms: The methylated histamine is the product, and making it lowers the amount of active histamine.
The immediate product of the reaction, N(tau)-methylhistamine, is a biologically less active metabolite that is further metabolised and excreted. By converting histamine to this methylated form, HNMT activity reduces the pool of free histamine available to bind histamine receptors, thereby terminating histamine signalling. In the brain, astrocytic HNMT contributes to histamine clearance and to the regulation of brain function.
Tissue-specific roles in histamine clearance
In simple terms: Different tissues use this enzyme to different extents to clear histamine.
HNMT is widely expressed, but its contribution to histamine clearance varies by tissue. In the brain, HNMT is a major histamine-inactivating enzyme, and astrocytic HNMT has been shown to contribute to histamine clearance and brain function in mice. In the gut, histamine metabolism is relevant to inflammatory bowel disease and to precision nutrition approaches. In the heart, HNMT upregulation has been associated with cardiac hypertrophy and heart failure.
Pharmacological modulation of the activity
In simple terms: Drugs can block this enzyme to keep histamine around longer.
Because HNMT activity terminates histamine signalling, pharmacological inhibition of HNMT has been explored as a way to enhance histaminergic signalling. In mouse models, pharmacological inhibition of HNMT extends wakefulness and suppresses cataplexy, supporting the idea that this enzymatic activity is a tractable drug target in sleep disorders. These findings illustrate how modulating GO:0046539 can produce measurable physiological effects.
Key Genes Involved in GO:0046539 histamine N-methyltransferase activity
The following genes and proteins are directly or indirectly involved in histamine N-methyltransferase activity, its regulation, or the histamine metabolic pathway in which it operates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HNMT | Encodes histamine N-methyltransferase, the enzyme that catalyses GO:0046539 | Central gene for knockout, point-mutation, knock-in and overexpression studies of histamine clearance |
| HDC | Encodes histidine decarboxylase, which synthesises histamine | Provides the substrate for HNMT and is relevant to histamine metabolism studies |
| DAO | Encodes diamine oxidase, an alternative histamine-degrading enzyme | Relevant to histamine intolerance and to comparative studies of histamine clearance |
| HRH1 | Histamine receptor H1 | Mediates histamine signalling that is terminated by HNMT activity |
| HRH2 | Histamine receptor H2 | Mediates histamine signalling in gastric and cardiac contexts |
| HRH3 | Histamine receptor H3 | Presynaptic receptor relevant to wakefulness and narcolepsy studies |
| HRH4 | Histamine receptor H4 | Mediates immune and inflammatory histamine effects |
| SLC22A3 | Organic cation transporter 3, involved in histamine transport | Relevant to histamine clearance and to HNMT substrate availability |
| SLC22A5 | Organic cation/carnitine transporter, involved in histamine transport | Relevant to histamine clearance studies |
| MAT1A | Methionine adenosyltransferase, involved in SAM synthesis | Provides the methyl donor for HNMT activity |
| AHCY | S-adenosylhomocysteine hydrolase, metabolises SAH | Relevant to the methylation cycle that supports HNMT activity |
| MTHFR | Methylenetetrahydrofolate reductase, supports methylation cycle | Relevant to one-carbon metabolism and SAM availability |
| COMT | Catechol-O-methyltransferase, another SAM-dependent methyltransferase | Comparative enzyme for methylation studies |
| TPH1 | Tryptophan hydroxylase 1, involved in serotonin synthesis | Relevant to amine metabolism comparisons |
| MAOA | Monoamine oxidase A, involved in amine oxidation | Relevant to comparative amine clearance studies |
| MAOB | Monoamine oxidase B, involved in amine oxidation | Relevant to comparative amine clearance studies |
| GAD1 | Glutamate decarboxylase 1, involved in GABA synthesis | Relevant to neurotransmitter metabolism comparisons |
| GAD2 | Glutamate decarboxylase 2, involved in GABA synthesis | Relevant to neurotransmitter metabolism comparisons |
How Is histamine N-methyltransferase activity Regulated?
HNMT activity is regulated at multiple levels. Transcriptionally, HNMT expression varies between tissues and can be altered in disease states such as cardiac hypertrophy and heart failure, where HNMT upregulation has been reported. At the metabolic level, the activity depends on the availability of the methyl donor S-adenosyl-L-methionine (SAM), which is produced through one-carbon metabolism, and it is inhibited by the product S-adenosyl-L-homocysteine (SAH). Pharmacological inhibition of HNMT has been used experimentally to modulate histamine clearance in sleep disorders, demonstrating that the activity can be regulated by small molecules. In the brain, astrocytic HNMT contributes to histamine clearance and brain function, indicating cell-type-specific regulation. In inflammatory bowel disease, histamine metabolism is influenced by nutritional and inflammatory factors, suggesting that diet and inflammation can regulate this activity.
histamine N-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HNMT | Histamine intolerance | HNMT knockout or point-mutation cell models and organoids |
| HNMT | Inflammatory bowel disease | Intestinal epithelial cell lines with HNMT knockout or overexpression |
| HNMT | Idiopathic hypersomnia | Neuronal cell models and mouse models with HNMT inhibition |
| HNMT | Narcolepsy | Mouse models of narcolepsy with pharmacological HNMT inhibition |
| HNMT | Cardiac hypertrophy and heart failure | Cardiomyocyte cell models with HNMT overexpression or knockout |
| HNMT | Breast cancer anti-HER2 response | Breast cancer cell lines with HNMT knockout or overexpression |
Histamine intolerance and inflammatory bowel disease
Histamine intolerance is a condition in which the capacity to degrade histamine is reduced, leading to adverse reactions to histamine-rich foods; HNMT activity is one of the key enzymes involved in histamine degradation. In inflammatory bowel disease, altered histamine metabolism has been linked to intestinal inflammation, and precision nutrition approaches are being explored to modulate histamine metabolism. These conditions illustrate how reduced or dysregulated GO:0046539 activity can contribute to disease.
Sleep disorders: idiopathic hypersomnia and narcolepsy
Histaminergic signalling promotes wakefulness, and HNMT activity terminates this signalling. Pharmacological inhibition of HNMT has been proposed as a novel therapeutic strategy for idiopathic hypersomnia, and in a mouse model of narcolepsy, pharmacological inhibition of HNMT extended wakefulness and suppressed cataplexy. These studies show that modulating GO:0046539 can directly affect sleep-wake phenotypes.
Cardiac hypertrophy and heart failure
HNMT upregulation has been reported in cardiac hypertrophy and heart failure, suggesting that altered histamine N-methyltransferase activity may contribute to cardiac pathology. This link expands the relevance of GO:0046539 beyond neurobiology and immunology into cardiovascular disease.
Breast cancer and anti-HER2 treatment response
HNMT has been identified as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients. This finding suggests that histamine N-methyltransferase activity may influence tumour biology or treatment response, although the underlying mechanisms require further investigation.
From histamine N-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HNMT activity alter histamine clearance? | HNMT knockout cell lines or organoids |
| Does a specific HNMT point mutation affect catalytic activity? | Point-mutation knock-in cell models |
| Does tagging HNMT affect its localisation or stability? | Tagged knock-in cell models |
| Does overexpression of HNMT reduce histamine signalling? | HNMT overexpression cell lines |
| Which genes modify the effects of HNMT loss? | CRISPR library screening in HNMT-mutant backgrounds |
| Can pharmacological inhibition of HNMT mimic genetic loss? | Cell and mouse models treated with HNMT inhibitors |
How to Study the histamine N-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Conversion of histamine to N(tau)-methylhistamine | Quantifying HNMT activity and testing inhibitors |
| CRISPR-Cas9 knockout | Loss of HNMT function | Establishing causal roles of HNMT in cells and organoids |
| Point-mutation knock-in | Effect of specific HNMT variants | Testing catalytic and regulatory mutations |
| Overexpression | Increased HNMT levels | Assessing effects of excess histamine clearance |
| Pharmacological inhibition | Acute reduction of HNMT activity | Studying wakefulness and cataplexy in animal models |
| Quantitative PCR | HNMT mRNA levels | Comparing expression across tissues and conditions |
| Western blotting | HNMT protein levels | Validating knockout or overexpression models |
| Immunohistochemistry | HNMT localisation in tissues | Mapping expression in brain and peripheral tissues |
Enzymatic activity assays
Histamine N-methyltransferase activity can be measured directly using biochemical assays that monitor the conversion of histamine to N(tau)-methylhistamine in the presence of SAM. These assays are used to quantify enzyme kinetics and to test inhibitors.
Genetic knockout and knockdown
CRISPR-Cas9 knockout or RNA interference can be used to reduce HNMT expression and assess the consequences for histamine clearance and downstream phenotypes. Such models are valuable for establishing causality.
Pharmacological inhibition
Small-molecule inhibitors of HNMT are used to acutely modulate enzyme activity in cells and animals. This approach has been applied in studies of wakefulness and cataplexy, demonstrating the physiological impact of reduced HNMT activity.
Expression and biomarker analysis
Quantitative PCR, western blotting and immunohistochemistry can be used to measure HNMT expression in tissues and cell models. In clinical samples, HNMT expression has been explored as a potential biomarker for anti-HER2 treatment response.
How CRISPR Can Be Used to Study GO:0046539 histamine N-methyltransferase activity
Knockout
CRISPR-Cas9 knockout of HNMT is used to eliminate histamine N-methyltransferase activity and to study the consequences for histamine clearance, signalling and downstream phenotypes. Such models are essential for establishing causality in disease-relevant pathways.
Point Mutation
Point-mutation knock-in can be used to introduce specific amino acid changes into HNMT to test their effects on catalytic activity, substrate binding or stability. This approach helps link genotype to enzymatic function.
Knock-in
Tagged knock-in of HNMT, for example with a fluorescent or affinity tag, allows researchers to track the enzyme's localisation, interactions and turnover in live cells and tissues.
Overexpression
Overexpression of HNMT in cell models can be used to increase histamine clearance and to test whether excess enzyme activity protects against histamine-driven phenotypes. This complements loss-of-function studies.
How EDITGENE Supports histamine N-methyltransferase activity Research
Researchers studying histamine N-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in histamine clearance, disease progression or treatment response. EDITGENE provides a comprehensive suite of CRISPR-based services to support these investigations, from knockout and point-mutation models to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for histamine N-methyltransferase activity research.
Frequently Asked Questions About histamine N-methyltransferase activity
What is histamine N-methyltransferase activity?
It is the enzymatic activity defined by GO:0046539 that catalyses the reaction S-adenosyl-L-methionine(1+) + histamine = N(tau)-methylhistamine + S-adenosyl-L-homocysteine + H+, the major route for histamine inactivation in mammals.
What gene encodes histamine N-methyltransferase?
The HNMT gene encodes histamine N-methyltransferase, the enzyme responsible for this activity.
What is the role of HNMT in the brain?
In the brain, HNMT contributes to histamine clearance, and astrocytic HNMT has been shown to regulate brain function in mice.
How is histamine N-methyltransferase activity linked to disease?
Altered HNMT activity has been associated with histamine intolerance, inflammatory bowel disease, idiopathic hypersomnia, narcolepsy, cardiac hypertrophy and heart failure, and breast cancer treatment response.
Can histamine N-methyltransferase be inhibited therapeutically?
Yes, pharmacological inhibition of HNMT has been explored as a strategy to extend wakefulness and suppress cataplexy in mouse models, and as a potential treatment for idiopathic hypersomnia.
What is the substrate of histamine N-methyltransferase?
The substrate is histamine, and the methyl donor is S-adenosyl-L-methionine.
What is the product of histamine N-methyltransferase activity?
The product is N(tau)-methylhistamine, along with S-adenosyl-L-homocysteine and a proton.
How can I study histamine N-methyltransferase activity in the lab?
Common methods include enzymatic activity assays, CRISPR knockout, point-mutation knock-in, overexpression, pharmacological inhibition and expression analysis.
Is HNMT a biomarker for cancer treatment?
HNMT has been identified as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients.
What are the synonyms for GO:0046539?
Synonyms include histamine 1-methyltransferase activity, histamine-methylating enzyme, histamine methyltransferase activity, imidazolemethyltransferase activity, S-adenosyl-L-methionine:histamine N-tele-methyltransferase activity and S-adenosylmethionine-histamine N-methyltransferase activity.
Conclusion
GO:0046539 histamine N-methyltransferase activity is a central molecular function in histamine metabolism, responsible for converting histamine to N(tau)-methylhistamine and thereby terminating histamine signalling. Its importance spans neurobiology, immunology, cardiovascular biology and oncology, with links to histamine intolerance, inflammatory bowel disease, sleep disorders, cardiac disease and cancer treatment response. Continued research using CRISPR-based models and pharmacological tools will clarify how this activity can be modulated for therapeutic benefit.
References
- 1. Maintz L et al.. 2007. Histamine and histamine intolerance.. Am J Clin Nutr 85(5):1185-96 PMID: 17490952
- 2. Yoshikawa T et al.. 2019. Histamine N-Methyltransferase in the Brain.. Int J Mol Sci 20(3) PMID: 30744146
- 3. Kanta D et al.. 2025. Histamine Metabolism in IBD: Towards Precision Nutrition.. Nutrients 17(15) PMID: 40806058
- 4. Girgin B et al.. 2026. Histamine N-methyltransferase inhibition as a novel therapeutic strategy for idiopathic hypersomnia.. Eur J Pharmacol 1011:178475 PMID: 41386465
- 5. Otsuka R et al.. 2022. Contribution of astrocytic histamine N-methyltransferase to histamine clearance and brain function in mice.. Neuropharmacology 212:109065 PMID: 35487272
- 6. Naganuma F et al.. 2025. Pharmacological inhibition of histamine N-methyltransferase extends wakefulness and suppresses cataplexy in a mouse model of narcolepsy.. Sleep 48(1) PMID: 39441998
- 7. Zhang J et al.. 2026. Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure.. Eur Heart J 47(19):2345-2363 PMID: 41568626
- 8. Cheng TC et al.. 2025. Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients.. Biomark Res 13(1):7 PMID: 39789599
